Managing Access to Medicines and Health Technologies
Contributors by Chapter

This list shows the technical contributors to each chapter and their professional affiliations and locations at the time of their contribution—not necessarily their current affiliation and location. Contributors are listed alphabetically, not in relation to the proportion of material they contributed. Many chapters retain a substantial proportion of text from the first two editions of this book. Authors from earlier editions are indicated by an asterisk. Authors who contributed to both the current and previous editions are indicated with a dagger.

1. Toward Sustainable Access to Medicines
   Martha Embrey, MSH, USA
   *Graham Dukes, Euro Health Group, Norway
   *Jonathan D. Quick, MSH, USA

2. Historical and Institutional Perspectives
   †Graham Dukes, University of Oslo, Norway
   Helena Walkowiak, MSH, USA
   *Ronald W. O’Connor, MSH, USA

3. Intellectual Property and Access to Medicines
   Sisule Musungu, South Centre, Switzerland

4. National Medicine Policy
   †Graham Dukes, University of Oslo, Norway
   *Pascale Brudon, World Health Organization (WHO), Switzerland

5. Traditional and Complementary Medicine Policy
   Torkel Faulkenberg, Karolinska Institutet, Sweden

6. Pharmaceutical Legislation and Regulation
   Enrique Fefer, Consultant, USA
   *Graham Dukes, Euro Health Group, Norway
   *Marcelo Vernengo, Universidad de Belgrano, Argentina
   *Robert L. Watt

7. Pharmaceutical Production Policy
   Martha Embrey, MSH, USA
   *John Holley, Integral Development Associates, USA
   *Paul J. N. Lamberts, Deventer Hospital Pharmacy, The Netherlands
   *Ronald W. O’Connor, MSH, USA
   *Robert L. Watt

8. Pharmaceutical Supply Strategies
   Malcolm Clark, MSH, Australia
   *Jonathan D. Quick, MSH, USA
   *James R. Rankin, MSH, USA
   *Germán Velásquez, WHO, Switzerland

9. Pharmaceutical Pricing Policy
   David Henry, University of Newcastle, Australia
   Andrew Searles, University of Newcastle, Australia

10. Economics for Pharmaceutical Management
    †David Henry, University of Newcastle, Australia
    *Kara Hanson, Harvard School of Public Health, USA
    *Jonathan D. Quick, MSH, USA
    *Germán Velásquez, WHO, Switzerland

11. Pharmaceutical Financing Strategies
    Martha Embrey, MSH, USA
    *William Newbrander, MSH, USA
    *Jonathan D. Quick, MSH, USA
    *Catriona Waddington, Overseas Development Administration, UK

12. Pharmaceutical Benefits in Insurance Programs
    John Chalker, MSH, UK

13. Revolving Drug Funds and User Fees
    Martha Embrey, MSH, USA
    *Margaret Hume, MSH, USA
    *Jennie I. Litvack, World Bank, USA
    *Jonathan D. Quick, MSH, USA

14. Global and Donor Financing
    Logan Brenzel, World Bank, USA
    *Enrique Fefer, Pan American Health Organization, USA
    *Margaret Hume, MSH, USA
    *Irene Klinger, Pan American Health Organization, USA
15. Pharmaceutical Donations
Malcolm Clark, MSH, Australia
Martha Embrey, MSH, USA
*Christel Albert
*Hans Hogerzeil, WHO, Switzerland

16. Managing Medicine Selection
Christopher Olson, MSH, USA
*Hans Hogerzeil, WHO, Switzerland

17. Treatment Guidelines and Formulary Manuals
Christopher Olson, MSH, USA
*Chris Forshaw, WHO, Malawi
*Hans Hogerzeil, WHO, Switzerland

18. Managing Procurement
Andrew Barraclough, MSH, Thailand
Malcolm Clark, MSH, Australia
*David Lee, MSH, USA
*Jonathan D. Quick, MSH, USA

19. Quality Assurance for Pharmaceuticals
Thomas Layloff, MSH, USA
*David Lee, MSH, USA
*Jonathan D. Quick, MSH, USA

20. Quantifying Pharmaceutical Requirements
Laila Akhlaghi, MSH, USA
*Christopher Olson, MSH, USA
*James R. Rankin, MSH, USA

21. Managing the Tender Process
Malcolm Clark, MSH, Australia
Ned Heltzer, MSH, USA
James Rankin, MSH, USA
*Johan van Haperen, Danida, Denmark

22. Managing Distribution
Malcolm Clark, MSH, Australia
*Anthony Battersby, Feilden Battersby Health Systems Analysts, UK
*James Bates, MSH, USA
*Andrew Garnett, Feilden Battersby Health Systems Analysts, UK

23. Inventory Management
Vimal Dias, MSH, Sri Lanka
*Jonathan D. Quick, MSH, USA
*James R. Rankin, MSH, USA

24. Importation and Port Clearing
†Hilary Vaughan, Crown Agents, UK
*Vimal Dias, MSH, Sri Lanka
*John Ellery, Greenshields Cowie, UK

25. Transport Management
Gabriel Daniel, MSH, USA
*Anthony Battersby, Feilden Battersby Health Systems Analysts, UK
*Andrew Garnett, Feilden Battersby Health Systems Analysts, UK

26. Kit System Management
Henk den Besten, IDA Solutions, The Netherlands
*Miguel de Clerck, Médecins sans Frontières, Switzerland
*Jean-Pierre de Lamalle, Médecins sans Frontières, Switzerland
*Myriam Henkens, Médecins sans Frontières, Switzerland
*Hans Hogerzeil, WHO, Switzerland
*Ignacio J. Packer, Médecins sans Frontières, Switzerland

27. Managing for Rational Medicine Use
John Chalker, MSH, UK
*Richard O. Laing, MSH, USA
*Budiono Santoso, Gadjah Mada University, Indonesia

28. Investigating Medicine Use
Lloyd Matowe, MSH, USA
*Dennis Ross-Degnan, Harvard University, USA

29. Promoting Rational Prescribing
John Chalker, MSH, UK
*Richard O. Laing, MSH, USA
*David Ofori-Adjei, University of Ghana Medical School, Ghana
*Christopher Olson, MSH, USA
*Budiono Santoso, Gadjah Mada University, Indonesia

30. Ensuring Good Dispensing Practices
†Paul Spivey, Consultant, UK

31. Community-Based Participation and Initiatives
Jane Briggs, MSH, Guatemala
*Aida Girma, United Nations Children’s Fund (UNICEF), USA

32. Drug Seller Initiatives
Malcolm Clark, MSH, USA
Ned Heltzer, MSH, USA
Keith Johnson, MSH, USA
Robert Staley, MSH, USA

33. Encouraging Appropriate Medicine Use by Consumers
Keith Johnson, MSH, USA
*Daphne A. Fresle, WHO, Switzerland
34. Medicine and Therapeutics Information
Keith Johnson, MSH, USA
*O. M. J. Kasilo, University of Zimbabwe Medical School, Zimbabwe

35. Pharmacovigilance
Christopher Olson, MSH, USA

36. Pharmaceutical Supply Systems Assessment
Martha Embrey, MSH, USA
*James R. Rankin, MSH, USA

37. Managing Pharmaceutical Programs
Sylvia Vriesendorp, MSH, USA
*Jonathan D. Quick, MSH, USA

38. Planning for Pharmaceutical Management
Malcolm Clark, MSH, Australia
*James Bates, MSH, USA
*A. Frederick Hartman
*Jonathan D. Quick, MSH, USA

39. Contracting for Pharmaceuticals and Services
Raj Gonsalkorale, Consultant, Australia
*Elvira Beracochea, MSH, USA
*Vimal Dias, MSH, Sri Lanka
*Sherita Gregoire, Goodwill, Dominica
*Jonathan D. Quick, MSH, USA

40. Analyzing and Controlling Pharmaceutical Expenditures
†James Rankin, MSH, USA
*Peter Graaff, WHO, Malawi
*Vimal Dias, MSH, Sri Lanka
*Jonathan D. Quick, MSH, USA

41. Financial Planning and Management
David J. Walsh, Consultant, UK
*David H. Collins, MSH, USA

42. Planning and Building Storage Facilities
†Andrew Garnett, Consultant, UK
*Jan F. Dik, Euro Health Group, Denmark
*Therese Edera-Piech, Design Development, Kenya

43. Security Management
Gabriel Daniel, MSH, USA
*Jonathan D. Quick, MSH, USA

44. Medical Stores Management
†Vimal Dias, MSH, Sri Lanka
*Anthony Battersby, Feilden Battersby Health Systems Analysts, UK

45. Hospital Pharmacy Management
†Christopher Olson, MSH, USA
*Anthony Savelli, MSH, USA

46. Pharmaceutical Management for Health Facilities
Jean-Pierre Sallet, MSH, South Africa
*Richard O. Laing, MSH, USA
*Hanif S. Nazerali

47. Laboratory Services and Medical Supplies
Catherine Mundy, MSH, USA
*Hans Hogerzeil, WHO, Switzerland
*Kirsten Myhr, University of Trondheim, Norway

48. Monitoring and Evaluation
Maria Miralles, MSH, USA
*Agnes B. Guyon, UNICEF, USA
*Jonathan D. Quick, MSH, USA

49. Pharmaceutical Management Information Systems
Julie Frye, MSH, USA
*David R. Wilson, MSH, USA

50. Computers in Pharmaceutical Management
†Julie Frye, MSH, USA
*Wilbert Bannenberg
*Paul Krystall, Data Dynamics, USA
*Jonathan D. Quick, MSH, USA
*James R. Rankin, MSH, USA
*Jean-Pierre Sallet, MSH, South Africa

51. Human Resources Management and Capacity Development
Ummuro Adano, MSH, USA
Mary O’Neil, MSH, USA
*Carl F. Browne, Ministry of Health and the Environment, St. Vincent and the Grenadines
*John Fox, Intermedia, USA

52. Designing and Implementing Training Programs
Ross Holland, MSH, USA
*Sam Muziki, WHO, Switzerland
*A. Frederick Hartman
### Reviewers

Reviewers provided feedback on one or more chapters. Reviewers’ professional affiliations and locations are from the time of their review—not necessarily their current affiliation and location. Their input does not necessarily reflect the views of their employers.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frances Aboagye-Nyame</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Syed Rizwanuddin Ahmad</td>
<td>USA</td>
<td>USA</td>
</tr>
<tr>
<td>Samvel Azatyan,</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Guitelle Baghdadi-Sabeti</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Andrew Barraclough</td>
<td>MSH, Thailand</td>
<td>Thailand</td>
</tr>
<tr>
<td>Hare Ram Bhattarai</td>
<td>MSH, Nepal</td>
<td>Nepal</td>
</tr>
<tr>
<td>Tina Brock</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Malcolm Bryant</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Robert Burn</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Edelisa Carandang</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Peter Carrasco</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>John Chalker</td>
<td>MSH, UK</td>
<td>UK</td>
</tr>
<tr>
<td>Malcolm Clark</td>
<td>MSH, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>Peter Cross</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Gabriel Daniel</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Vimal Dias</td>
<td>MSH, Sri Lanka</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>Alex Dodoo</td>
<td>University of Ghana</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Medical School, Ghana</td>
<td>USA</td>
</tr>
<tr>
<td>Alison Ellis</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Marthe Everard</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Julie Frye</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Michael Gabra</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Louis Garrison</td>
<td>University of Washington</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>School of Pharmacy, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Natalie Gaul</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Nigel Gericke</td>
<td>Consultant, South Africa</td>
<td></td>
</tr>
<tr>
<td>Raj Gonsalkorale</td>
<td>Consultant, Australia</td>
<td></td>
</tr>
<tr>
<td>Ned Heltzer</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Suzanne Hill</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Hans Hogerzeil</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Kathleen Holloway</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Keith Johnson</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Mohan Joshi</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Charles Kagoma,</td>
<td>MSH, Tanzania</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Grace Kahenya</td>
<td>MSH, Zambia</td>
<td>Zambia</td>
</tr>
<tr>
<td>Richard Laing</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Rama Lakshminarayanan</td>
<td>World Bank, USA</td>
<td>USA</td>
</tr>
<tr>
<td>David Lee</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Evan Lee</td>
<td>MSH, France</td>
<td>France</td>
</tr>
<tr>
<td>Andrew Marsden</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Lloyd Matowe</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Thomas Moore</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Gail Naimoli</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Bannet Ndyanabangi</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>William Newbrander</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Christopher Olson</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia Paredes,</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Alain Prat</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Jonathan Quick</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>James Rankin</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Steve Reed</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Andreas Seiter</td>
<td>World Bank, USA</td>
<td>USA</td>
</tr>
<tr>
<td>John Sheptor</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Rima Shretta</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Anthony So</td>
<td>Duke University, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Robert Staley</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Helen Tata</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Linda Tawfik</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Dat Tran</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Anita Wagner</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Helena Walkowiak</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Hella Witt</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Andre Zagorski</td>
<td>MSH, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Xiaorui Zhang</td>
<td>WHO, Switzerland</td>
<td>Switzerland</td>
</tr>
</tbody>
</table>
Contents

Preface
How to Use MDS-3

Part I Policy and Economic Issues

Policy and Legal Framework
1. Toward Sustainable Access to Medicines
2. Historical and Institutional Perspectives
3. Intellectual Property and Access to Medicines
4. National Medicine Policy
5. Traditional and Complementary Medicine Policy
6. Pharmaceutical Legislation and Regulation
7. Pharmaceutical Production Policy
8. Pharmaceutical Supply Strategies

Financing and Sustainability
9. Pharmaceutical Pricing Policy
10. Economics for Pharmaceutical Management
11. Pharmaceutical Financing Strategies
12. Pharmaceutical Benefits in Insurance Programs
13. Revolving Drug Funds and User Fees
14. Global and Donor Financing
15. Pharmaceutical Donations

Part II Pharmaceutical Management

Selection
16. Managing Medicine Selection
17. Treatment Guidelines and Formulary Manuals

Procurement
18. Managing Procurement
19. Quality Assurance for Pharmaceuticals
20. Quantifying Pharmaceutical Requirements
21. Managing the Tender Process

Distribution
22. Managing Distribution
23. Inventory Management
24. Importation and Port Clearing
25. Transport Management
26. Kit System Management

Use
27. Managing for Rational Medicine Use
28. Investigating Medicine Use
29. Promoting Rational Prescribing
30. Ensuring Good Dispensing Practices
31. Community-Based Participation and Initiatives
32. Drug Seller Initiatives
33. Encouraging Appropriate Medicine Use by Consumers
34. Medicine and Therapeutics Information
35. Pharmacovigilance

Part III Management Support Systems

Planning and Administration
36. Pharmaceutical Supply Systems Assessment
37. Managing Pharmaceutical Programs
38. Planning for Pharmaceutical Management
39. Contracting for Pharmaceuticals and Services
40. Analyzing and Controlling Pharmaceutical Expenditures
41. Financial Planning and Management
42. Planning and Building Storage Facilities

Organization and Management
43. Security Management
44. Medical Stores Management
45. Hospital Pharmacy Management
46. Pharmaceutical Management for Health Facilities
47. Laboratory Services and Medical Supplies

Information Management
48. Monitoring and Evaluation
49. Pharmaceutical Management Information Systems
50. Computers in Pharmaceutical Management

Human Resources Management
51. Human Resources Management and Capacity Development
52. Designing and Implementing Training Programs

Index
Preface

It is my great pleasure to present MDS-3: Managing Access to Medicines and Health Technologies. In the thirty years since the original publication of Managing Drug Supply, the world has experienced remarkable changes as the global health context has evolved. Think, for example, about the profound impact that HIV/AIDS alone has had. Advances in science and medicine, donor funding for vast global health initiatives, the advent of innovative information technologies, and a greater focus on building strong health systems have fundamentally affected our work. What has not changed over the years is MSH’s commitment to identifying problems in access to and use of medicines and designing and implementing relevant, effective responses. We hope that MDS-3 will be a valuable tool in the effort to ensure universal access to quality medicines and health technologies and their appropriate use.

The new and updated information in MDS-3 reflects the dramatic changes in the public health landscape. Nearly 100 experts from a wide range of disciplines and virtually every corner of the world have contributed to this third edition. In addition to new country studies, references, and extensive revisions, MDS-3 offers new chapters on areas such as pharmaceutical benefits in insurance programs, pricing, intellectual property, drug seller initiatives, and traditional and complementary medicine. The revisions and new chapters echo the wide variety of issues that are important to health practitioners and policy makers today. Even the book’s new title depicts the need to broaden our focus from medicines to include health technologies, such as test kits and laboratory supplies, and to embrace the concept of access. Too often people assume that if medicines and technologies are available, positive health outcomes will naturally result. Access, however, encompasses not only product availability, but also the need to provide medicines and pharmaceutical services that are safe, efficacious, cost-effective, and high quality. Equally important are affordability and acceptability, including cultural and personal preferences.

We hope that MDS-3 will be used widely by those with an interest in improving access to medicines and health technologies. To make the book accessible to as many users as possible, we are making the content available in several formats. The easiest way to access MDS-3 is online at http://www.mds-online.org. The entire book can be searched online, and individual chapters can be downloaded. MDS-3 is also available directly from MSH on flash drive or CD-ROM for those without reliable Internet access or who prefer these media. We are working on an arrangement to make print copies available as well.

As users of MDS-3, you are vital to ensuring that it remains a valuable and dynamic resource. Your suggestions for enriching and updating the information and improving its presentation are greatly welcome. We will update individual chapters as needed to provide new material in a timely manner. Please send suggestions to us at mds@msh.org.

We acknowledge with great appreciation all the authors, reviewers, and others whose efforts are reflected in MDS-3. Any contribution that MDS-3 makes is a direct result of their knowledge, experience, and deep dedication—and of the hard work of those around the world who each day strive to help their countries and their programs realize the full health impact of ensuring access to medicines and health technologies for all.

Jonathan D. Quick, MD, MPH
President and Chief Executive Officer
Management Sciences for Health
February 2012
How to Use *MDS-3*

*MDS-3: Managing Access to Medicines and Health Technologies* may seem intimidating, but you do not need to read it from cover to cover. To ease accessibility, we have organized its content to present a sequential overview of major topics and then within each section to provide more detailed explanations of fundamental concepts, definitions of basic terms, and practical ideas for designing and implementing effective changes in pharmaceutical management systems.

The following features make the material accessible to readers looking for information in specific areas.

**Overview chapters.** Starting with Part II, Pharmaceutical Management, overview chapters introduce each element in the pharmaceutical management framework: selection (Chapter 16), procurement (Chapter 18), distribution (Chapter 22), use (Chapter 27), and management (Chapter 37). These overview chapters provide background information that lays the foundation for more detailed discussions of specific topics in the chapters that follow them.

**Chapter summaries.** Each chapter begins with a summary of its contents. Readers who are interested in a brief overview of an area or of all aspects of managing access to medicines can read the relevant summaries.

**Country studies.** Reports of experiences in various countries illustrate points in the text. Although conditions in some countries may have changed since these country studies were written, they provide useful examples of the ways in which the pharmaceutical management process can operate, and in some cases, how it should not operate.

**Boxes.** Boxes are used to make information, such as the steps of a process, easy to locate and use. In addition, some boxes contain general experiences or descriptions of relevant initiatives or resources.

**Glossaries.** Glossaries are included for the chapters on intellectual property (Chapter 3), insurance (Chapter 12), selection (Chapter 16), procurement (Chapter 18), distribution (Chapter 22), use (Chapter 27), management (Chapter 37), analyzing expenditures (Chapter 40), financial management (Chapter 41), storage facilities (Chapter 42), and computers (Chapter 51).

**References and further readings.** Each chapter contains a list of references cited in the text or that relate to topics the chapter covers. Particularly useful references are indicated by a star.

**Chapter annexes.** Annexes provide sources of additional information and samples of pharmaceutical management forms currently in use in various parts of the world.